• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 7

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

The Psychedelic News Feed: January 5 – June 1, 2025

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term...

Psychedelics in Japan: Dr. Hiroyuki Uchida on Studies, Stigma, and the...

Paul Gillis-Smith – Psychedelics, Religion & Lisa Bieberman

FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies

Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms,...

The Interdisciplinary Annotated Psychedelic Research Bibliography of 2024

Reflections on the 2025 Federal Policy Summit on Psychedelic Medicine

Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as...

Dr Simon Ruffell – Other Ways of Knowing

1...678...294Page 7 of 294

EDITOR PICKS

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK...

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©